Otsuka America

What Otsuka America does

Otsuka America Pharmaceutical, Inc. is the US commercial and R&D subsidiary of Japan's Otsuka Pharmaceutical Co., Ltd. (TSE: 4578), operating as a specialty pharmaceutical company focused on three therapeutic pillars: central nervous system (CNS) disorders, nephrology, and immunology. The company develops, manufactures, and markets a portfolio of branded small-molecule and biologic therapies, anchored by long-acting injectable and oral antipsychotics (ABILIFY franchise, REXULTI), the first FDA-approved treatment to slow progression of autosomal dominant polycystic kidney disease (JYNARQUE/SAMSCA/tolvaptan), the first-in-class selective APRIL inhibitor VOYXACT for IgA nephropathy, and the digital therapeutic Rejoyn for major depressive disorder (developed with Click Therapeutics). Its technology base spans proprietary platforms including APRIL inhibition, norepinephrine-dopamine-serotonin reuptake inhibition (centanafadine), antibody engineering (Visterra subsidiary), the RAPID chemoproteomics screening platform (Jnana Therapeutics, acquired 2024), and rapid-acting neuroplastogens (TSND-201/methylone for PTSD, acquired via Transcend Therapeutics in 2026).

Revenue is generated through prescription pharmaceutical product sales distributed via major US wholesalers (Cardinal Health, McKesson, Cencora) and specialty pharmacies (PANTHERx Rare, Eversana), supplemented by patient support services through the Otsuka Patient Support Program and the nonprofit Otsuka Patient Assistance Foundation (OPAF). Strategic alliances contribute licensing and co-development revenue, most notably the long-standing Lundbeck CNS alliance (since 2011, yielding five co-developed therapies) and the Click Therapeutics digital therapeutics collaboration. The company serves healthcare professionals and patients in mental health (PsychU community with 75,000+ members), nephrology (NephU community), and Alzheimer's disease (Global Council on Alzheimer's Disease), with growing emphasis on caregiver advocacy through programs like Society of Valued Minds and NEXUS.

Operationally, Otsuka America runs from Princeton, NJ (headquarters), Rockville, MD, and Hayward, CA, with 1,001-5,000 US employees. Its business model blends cash-generative legacy assets (ABILIFY/REXULTI/JYNARQUE) funding aggressive pipeline replenishment through M&A - notably the $1.1B Jnana Therapeutics acquisition (August 2024) and $1.225B Transcend Therapeutics acquisition (completed June 2026) - alongside partnership-based pipeline expansion and proprietary R&D across novel mechanisms for CNS, rare kidney disease, and immunology indications.

Name

Otsuka America

Legal name

Otsuka America Pharmaceutical, Inc.

Website

https://otsuka-us.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Otsuka America Pharmaceutical, Inc. is the US subsidiary of Japan's Otsuka Pharmaceutical Co., Ltd., developing and commercializing branded therapies for CNS, nephrology, and immunology disorders including the ABILIFY/REXULTI antipsychotic franchises, JYNARQUE for ADPKD, VOYXACT for IgA nephropathy, and digital therapeutic Rejoyn for depression.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceuticals
• Neuroscience therapies
• Nephrology treatments
• Rare disease therapeutics
• Prescription digital therapeutics

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Revenue from sales of branded pharmaceutical products including ABILIFY, JYNARQUE, VOYXACT, REXULTI, and other approved therapies through wholesale distribution and specialty pharmacy channels.
2. Licensing and Alliance Revenue: Revenue from strategic alliances including Lundbeck global alliance for CNS products and Click Therapeutics digital therapeutic partnership. Includes co-development and commercialization arrangements.
3. Patient Support Services: Otsuka Patient Support Program and Otsuka Patient Assistance Foundation (OPAF) provide treatment support, insurance navigation, and financial assistance to patients prescribed Otsuka medications.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels9 records

Core offering

Otsuka America develops, manufactures, and commercializes FDA-approved prescription pharmaceuticals for central nervous system disorders (ABILIFY, REXULTI, NUEDEXTA) and nephrology/immunology conditions (JYNARQUE, VOYXACT), along with pipeline assets including centanafadine for ADHD and TSND-201 for PTSD. The company also distributes a prescription digital therapeutic (Rejoyn for MDD) and operates patient support programs and professional education communities serving patients, caregivers, and healthcare providers across the United States.

Product overview

Otsuka America Pharmaceutical is a pharmaceutical company offering a portfolio of FDA-approved medications across CNS/neuroscience and nephrology/immunology therapeutic areas. The approved product portfolio includes ABILIFY (aripiprazole) and its long-acting formulations (ABILIFY MAINTENA, ABILIFY ASIMTUFII), REXULTI (brexpiprazole), NUEDEXTA, JYNARQUE/SAMSCA (tolvaptan), VOYXACT (sibeprenlimab-szsi), and IV BUSULFEX. The pipeline includes centanafadine for ADHD under FDA priority review, TSND-201 for PTSD acquired through Transcend Therapeutics, brexpiprazole for PTSD, ulotaront for schizophrenia/depression, and treatments for PKU, epilepsy, and other conditions. Additionally, Otsuka offers digital health solutions including Rejoyn (prescription digital therapeutic for MDD with Click Therapeutics), professional education communities (PsychU, NephU), and advocacy initiatives.

Differentiator

Problem solved

Functional benefit

Brands

• Visterra: Clinical-stage biotechnology company developing innovative antibody-based therapies for kidney diseases and other hard-to-treat conditions.
• McQuade Center for Strategic Research & Development (MSRD)
• PsychU
• NephU

Products and services

• ABILIFY (aripiprazole) Antipsychotic medication approved for treating schizophrenia, bipolar disorder, and as adjunctive treatment for major depressive disorder in adults. Sold through wholesale distribution.
• ABILIFY MAINTENA (aripiprazole) Extended-release once-monthly injectable formulation of aripiprazole for schizophrenia and bipolar I disorder maintenance treatment.
• ABILIFY ASIMTUFII (aripiprazole) Extended-release injectable suspension administered every two months for schizophrenia and bipolar I disorder, providing the longest dosing interval in the aripiprazole LAI franchise.
• REXULTI (brexpiprazole) Atypical antipsychotic for treating schizophrenia in adults and as adjunctive therapy for major depressive disorder in adults, commercialized under the Otsuka-Lundbeck global CNS alliance.
• JYNARQUE (tolvaptan) Oral selective vasopressin V2 receptor antagonist and the first FDA-approved treatment to slow kidney function decline in rapidly progressing ADPKD. Distributed through specialty pharmacy Eversana.
• VOYXACT (sibeprenlimab-szsi) Selective APRIL (A-Proliferation-Inducing Ligand) inhibitor and the first FDA-approved treatment for primary IgA nephropathy, administered as a subcutaneous injection and dispensed exclusively through PANTHERx Rare Pharmacy.
• SAMSCA (tolvaptan) Oral selective vasopressin V2 receptor antagonist approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremia.
• NUEDEXTA (dextromethorphan HBr and quinidine sulfate) Fixed-dose combination of dextromethorphan hydrobromide and quinidine sulfate approved for the treatment of pseudobulbar affect (PBA), characterized by sudden, uncontrollable episodes of crying or laughing.
• IV BUSULFEX (busulfan) Intravenous chemotherapy conditioning agent administered in combination with other chemotherapy prior to allogeneic hematopoietic progenitor cell transplantation for chronic myeloid leukemia.
• Rejoyn Prescription digital therapeutic co-developed with Click Therapeutics that delivers a software-based cognitive-emotional training program as an adjunctive treatment for major depressive disorder in adults on antidepressant medication.

Quantifiable outcome

• VOYXACT achieved negative microscopic hematuria in 82.5% of patients at 48 weeks vs 52.6% on placebo, with median time to negativity of 9 weeks vs 24 weeks
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core.

• Transcend TherapeuticscoreStrategic or Co-development Partner · 27 March 2026Transcend Therapeutics acquired by Otsuka America (subsidiary of Otsuka Pharmaceutical) for $700 million upfront plus up to $525 million in contingent payments. Transcend is a clinical-stage biotech developing TSND-201 (methylone) for PTSD treatment, which received FDA Breakthrough Therapy Designation in 2025. Transaction completed June 12, 2026.
• Jnana TherapeuticscoreStrategic or Co-development Partner · 1 January 2024Jnana Therapeutics acquired by Otsuka Pharmaceutical in August 2024 for $800 million plus up to $325 million in milestones. Jnana operates as a wholly owned subsidiary in Boston continuing R&D activities. Uses RAPID (Reactive Affinity Probe Interaction Discovery) platform for drug discovery in PKU and autoimmune diseases.
• Click TherapeuticscoreStrategic or Co-development Partner · 1 January 2020Strategic alliance for developing and commercializing prescription digital therapeutics for treating major depressive disorder (MDD). Combines Click Therapeutics' expertise in software application development with Otsuka's commitment and expertise in mental illness research, development, and commercialization. REJOYN was authorized by FDA in 2024 as the first prescription digital therapeutic for MDD.
• VisterracoreStrategic or Co-development Partner · 1 January 2018Visterra is a clinical-stage biotechnology company acquired by Otsuka in 2018 to develop innovative antibody-based therapies for patients with kidney diseases and other hard-to-treat conditions. Pipeline includes programs targeting IgA nephropathy, kidney diseases, cancer, chronic pain, and infectious diseases. Visterra operates as a wholly owned subsidiary.
• PANTHERx Rare PharmacycoreChannel Partner/ Reseller/ Distributor · 1 January 2018PANTHERx Rare Pharmacy selected as exclusive pharmacy to dispense VOYXACT (sibeprenlimab-szsi) for treatment of primary immunoglobulin A nephropathy. This collaboration continues a relationship dating back to 2018, focusing on personalized care for rare disease patients.
• LundbeckcoreStrategic or Co-development Partner · 1 January 2011Global alliance agreement established in 2011 between Otsuka and Lundbeck focusing on CNS treatments. Both companies share focus on mental health disorders. The alliance has resulted in co-development and commercialization of 5 psychiatric and neurologic therapies worldwide. Otsuka and Lundbeck take an unconventional approach to develop and commercialize treatments for patients with CNS disorders.
• McQuade Center for Strategic Research & Development (MSRD)coreStrategic or Co-development PartnerMSRD is a US limited-liability company established to identify and fund innovative early-stage research and development programs as building blocks for future Otsuka products. Named for Robert McQuade, PhD.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Biogen: Specialty pharmaceutical company with strong CNS and rare disease focus (multiple sclerosis, Alzheimer's, spinal muscular atrophy). Comparable therapeutic specialization and high-impact branded biologics approach.
• H. Lundbeck: Danish pharmaceutical company specializing in CNS disorders, with a global alliance with Otsuka dating back to 2011 that has produced 5 psychiatric and neurologic therapies including REXULTI and brexpiprazole. Most direct comparable given shared CNS focus and commercial collaboration.
• Sumitomo Pharma: Japanese pharmaceutical company with strong CNS and mental health focus, including treatments for schizophrenia, depression, and ADHD. Comparable therapeutic area focus and Japanese parent company heritage similar to Otsuka.

Emerging players

• Click Therapeutics: Digital therapeutics company that developed REJOYN (FDA-authorized 2024 for MDD) in partnership with Otsuka. Comparable as Otsuka's digital therapeutic partner and emerging DTx player.
• Sage Therapeutics: CNS-focused biopharmaceutical company developing novel therapies for depression and neurology indications. Comparable in CNS pipeline development and focus on novel mechanisms of action.
• Ionis Pharmaceuticals: Antisense technology company developing RNA-targeted therapeutics, with collaboration with Otsuka on ulefnersen for FUS-ALS. Comparable as a partner in Otsuka's CNS pipeline development.

Broad incumbents

• Daiichi Sankyo: Major Japanese pharmaceutical company with global operations and specialty care focus. Comparable as a Japanese parent with significant US pharmaceutical subsidiary operations.
• Takeda Pharmaceutical: Major Japanese pharmaceutical company with diversified CNS franchise (including ADHD treatment VYVANSE through Shire acquisition), nephrology presence, and large US operations. Comparable in scale and Japanese parent company structure.
• Astellas Pharma: Major Japanese pharmaceutical company with diversified portfolio including specialty and rare disease franchises. Comparable as a Japanese parent with US commercial operations and similar pipeline expansion strategy.
• Bristol-Myers Squibb: Major global pharmaceutical company with historical CNS franchise (including legacy ABILIFY partnership) and diversified therapeutic areas. Comparable broad pharma scale and US commercial infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/otsukaus
• YouTubeyoutube.com/channel/UCSMEX6Q10v5ehZSKsN-Odwg
• Facebookfacebook.com/OtsukaUS
• LinkedInlinkedin.com/company/otsuka-pharmaceutical-companies
• Instagraminstagram.com/otsuka_us

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka America